Researchers overseeing the trial at Roswell Park discuss the effectiveness of CIMAvax-EGF in NSCLC, the results of completed clinical trials in Cuba, and the long-term plans for additional testing of the vaccine.
Elizabeth J. Shpall, MD, of The University of Texas MD Anderson Cancer Center, and Mary K. Gospodarowicz, MD, of the Princess Margaret Cancer Centre, Canada, are the 2017 recipients of the Women Who Conquer Cancer Mentorship Award.
The 2011 ASCO Annual Meeting Plenary Session ushered in a renaissance for melanoma therapy with the promise of targeted therapy. Results of the BRIM-3 trial marked the beginning of the end of cytotoxic chemotherapy for melanoma.
Dr. Eric Kmiec summarizes advances in real-time gene editing and cancer immunotherapy. Such advances, including CTLA-4 and PD-1 blockade, as well as CRISPR/Cas9 and CAR-based manipulations, are being explored in multiple ongoing clinical trials worldwide.
SIOPEN results presented at the 2011 ASCO Plenary Session changed the standard of care for high-risk neuroblastoma in Europe but not in North America. Standard of care in North America now is tandem autologous stem cell transplants.